Bristol Myers Squibb Phase 3 Shows 59% Lower PFS Risk vs Chemotherapy
Izalontamab brengitecan reduced the risk of progression or death by 59% in HR+/HER2- breast cancer. Median progression-free survival was 8.2 months versus 4.0 months with chemotherapy (HR 0.41; p<0.0001); overall survival data are immature.
Story updates
11:53:31 AM UTC
SquawkNews
Bristol Myers, SystImmune drug cuts breast cancer progression risk in study
Bristol Myers Squibb said izalontamab brengitecan reduced the risk of disease progression or death by 59% compared with chemotherapy in HR+/HER2- breast cancer. Median progression-free survival was 8.2 months versus 4.0 months (HR 0.41; p<0.0001). Overall survival data remain immature.